New drug combo shows promise for tough prostate cancer
NCT ID NCT02893917
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding cediranib to olaparib works better than olaparib alone for men with metastatic castration-resistant prostate cancer. Olaparib blocks DNA repair in cancer cells, while cediranib stops tumor blood vessel growth. The study involves 90 participants and measures how long the cancer stays controlled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cediranib and olaparib
- What this could lead to
- If successful, this combination could offer a new treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy.
- What could go wrong
- This is a mid-stage trial with only 90 participants, so results may not apply to everyone. The combination may cause more side effects than olaparib alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PROSTATE ADENOCARCINOMA WITH NEUROENDOCRINE DIFFERENTIATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Smilow Cancer Center/Yale-New Haven Hospital
New Haven, Connecticut, 06510, United States
-
UC San Diego Medical Center - Hillcrest
San Diego, California, 92103, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, 23298, United States
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
-
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Weisberg Cancer Treatment Center
Farmington Hills, Michigan, 48334, United States
-
Yale University
New Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a three-drug cocktail outsmart resistant prostate cancer?
- New hope for advanced bladder cancer? bevacizumab combo tested
- Supercharged immune cells take on Hard-to-Treat prostate cancer
- New combo therapy aims to delay return of spread prostate cancer
- New PET scan agent aims to map hidden prostate cancer spread